Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Non-cash Items (2019 - 2025)

Historic Non-cash Items for BridgeBio Pharma (BBIO) over the last 7 years, with Q2 2025 value amounting to $10.9 million.

  • BridgeBio Pharma's Non-cash Items fell 8349.36% to $10.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $10.9 million, marking a year-over-year decrease of 8349.36%. This contributed to the annual value of $10.3 million for FY2024, which is 1686.29% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Non-cash Items of $10.9 million as of Q2 2025, which was down 8349.36% from $130.9 million recorded in Q1 2025.
  • BridgeBio Pharma's 5-year Non-cash Items high stood at $178.6 million for Q4 2023, and its period low was $2.0 million during Q1 2021.
  • Its 5-year average for Non-cash Items is $36.7 million, with a median of $9.6 million in 2021.
  • As far as peak fluctuations go, BridgeBio Pharma's Non-cash Items plummeted by 9683.37% in 2021, and later soared by 785164.74% in 2023.
  • Over the past 5 years, BridgeBio Pharma's Non-cash Items (Quarter) stood at $10.1 million in 2021, then crashed by 77.87% to $2.2 million in 2022, then surged by 7851.65% to $178.6 million in 2023, then plummeted by 94.25% to $10.3 million in 2024, then increased by 6.26% to $10.9 million in 2025.
  • Its last three reported values are $10.9 million in Q2 2025, $130.9 million for Q1 2025, and $10.3 million during Q4 2024.